These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33142245)

  • 1. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
    Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
    Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
    Salavisa M; Serrazina F; Ladeira AF; Correia AS
    Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
    Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
    Coerver EME; Bourass A; Wessels MHJ; van Kempen ZLE; Jasperse MMS; Tonino BAR; Barkhof F; Mostert J; Uitdehaag BMJ; Killestein J; Strijbis EMM
    Mult Scler Relat Disord; 2023 Jun; 74():104706. PubMed ID: 37068370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.
    Monschein T; Salhofer-Polanyi S; Altmann P; Zrzavy T; Dal-Bianco A; Bsteh G; Rommer P; Berger T; Leutmezer F
    J Neurol; 2021 Apr; 268(4):1247-1253. PubMed ID: 32929591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
    Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
    Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care.
    Ozen NPA; Dursun EG; Tuncer A; Karabudak R
    Mult Scler Relat Disord; 2024 Apr; 84():105503. PubMed ID: 38422633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    Chappuis M; Rousseau C; Bajeux E; Wiertlewski S; Laplaud D; Le Page E; Michel L; Edan G; Kerbrat A
    J Neurol; 2023 Jan; 270(1):413-422. PubMed ID: 36121558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
    J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
    Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
    JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
    Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
    Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.